UPC_CFI_8/2023

PROSTHETIC VALVE

InfringementMain Infringement ActionNordic-Baltic RDInfringementCase ClosedSettled at: Pre-any-decision

Overview Decisions Reasoning Citations Documents Timeline

Coverage: Thin.Reasoning extracted with limited coverage — see decisions tab for full text.

Plain-English summary

Edwards Lifesciences Corporation brought a UPC infringement action before the Nordic-Baltic Regional Division against Meril Lifesciences and related entities concerning EP 2628464 (a prosthetic heart valve), with defendants filing counterclaims for revocation. Following a stay pending EPO Technical Board of Appeal proceedings (TBA upheld the patent in June 2024), the parties reached a confidential settlement agreement in July 2025. The court confirmed the settlement by decision covering both the infringement action and all four counterclaim workflows, and ordered partial reimbursement of court fees.

Accepted arguments

What the court agreed with — by party.

No accepted arguments captured.

Rejected arguments

What the court did not agree with — and why.

No rejected arguments captured.

Key legal principles

Doctrines and rules cited in the reasoning.

Parties may settle and dispose of proceedings without seeking a court-confirmatory decision under Rule 365 RoP Settlement confirmed by court decision can cover both infringement action and counterclaims for revocation 20% court fee reimbursement available on settlement under Rule 370.9(c) RoP

Browse other cases on this principle.